Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Charles F McHugh"'
Autor:
Peter A. Jones, Ashley K. Wiseman, Helai P. Mohammad, Christopher S. Kershaw, Bryan W. King, Ian D. Waddell, Thau F. Ho, Stephen B. Baylin, Morris Muliaditan, Marcus Bantscheff, Elisabeth A. Minthorn, Thilo Werner, Alan P. Graves, Wendy A. Kellner, Phil Chapman, Mehul Patel, Anthony J. Jurewicz, Allan M. Jordan, Emma E. Fairweather, Rab K. Prinjha, Nino Campobasso, Anna Rutkowska, H. Christian Eberl, Ryan G. Kruger, Charles F. McHugh, Michael T. McCabe, Kristin M. Goldberg, Jon Paul Jaworski, Christopher L. Carpenter, Michael Steidel, Stuart Paul Romeril, Dirk A. Heerding, Lourdes Rueda, David T. Fosbenner, Amy N. Taylor, Jacques Briand, Shawn W. Foley, Arthur Groy, Andrew B. Benowitz, Xiaodong Cheng, Donald J. Ogilvie, Paola Grandi, Cunyu Zhang, Mei Li, Sarath Pathuri, Aidan G. Gilmartin, Christian S. Sherk, Juan I. Luengo, Mark Cockerill, Ali Raoof, Alexandra Stowell, Kathryn Keenan, Melissa B. Pappalardi, Makda Mebrahtu, Kristen Wong, Xing Zhang, Jessica L. Handler, Roger J. Butlin, John R. Horton, Susan Merrihew, Charlotte Burt, Dean E. McNulty
Publikováno v:
Nature Cancer. 2:1002-1017
DNA methylation, a key epigenetic driver of transcriptional silencing, is universally dysregulated in cancer. Reversal of DNA methylation by hypomethylating agents, such as the cytidine analogs decitabine or azacytidine, has demonstrated clinical ben
Autor:
Kristen Wong, Jessica L. Handler, Michael T. McCabe, Helai P. Mohammad, Bryan W. King, Dirk A. Heerding, Melissa B. Pappalardi, Ryan G. Kruger, Lourdes Rueda, Mehul Patel, David T. Fosbenner, Allan M. Jordan, Elisabeth A. Minthorn, Andrew B. Benowitz, Kathryn Keenan, Christian S. Sherk, Ali Raoof, Charlotte Burt, Alexandra Stowell, Mark Cockerill, Jacques Briand, Charles F. McHugh, Rab K. Prinjha
Publikováno v:
Cancer Research. 78:2994-2994
Aberrant DNA hypermethylation within promoter regions and subsequent gene silencing are near universal hallmarks of human cancer. Reversal of DNA methylation by a hypomethylating agent, such as decitabine (Dacogen) or azacytidine (Vidaza), has shown
Autor:
Thau F. Ho, Yan Liu, Xinrong Tian, Patrick McDevitt, Michael Butticello, Timothy K. Hart, Kimberly N. Smitheman, David Soong, Jessica L. Schneck, Peter J. Tummino, Christine L. Hann, Glenn S. Van Aller, Yuchen Bai, Nestor O. Concha, Kasparec Jiri, Melissa B. Pappalardi, Christopher L. Carpenter, Mcnulty Kenneth C, Kelly Federowicz, Jeffrey D. Carson, William H. Miller, Johnson Neil W, Chandrashekhar D. Kamat, Rouse Meagan B, Charles F. McHugh, Michael T. McCabe, Ryan G. Kruger, Dashyant Dhanak, Helai P. Mohammad, Michelle Crouthamel, Yan Degenhardt, William G. Bonnette, Shelby A. Gorman
Publikováno v:
Cancer cell. 28(1)
SummaryEpigenetic dysregulation has emerged as an important mechanism in cancer. Alterations in epigenetic machinery have become a major focus for targeted therapies. The current report describes the discovery and biological activity of a cyclopropyl
Autor:
Susan Korenchuk, Alexander Joseph Reif, Juan I. Luengo, Cynthia M. Rominger, Angela Smallwood, Nestor O. Concha, Alan R. Rendina, Schmidt Stanley J, Huizhen Zhao, Chad Quinn, Charles F. McHugh, Michael T. McCabe, Beth Pietrak, Benjamin Schwartz, Christopher L. Carpenter, Ken Wiggall, Hongwei Qi, Ryan G. Kruger, Enoch Gao, Nicholas D. Adams, Arthur Groy
Publikováno v:
Cancer Research. 75:3514-3514
The isocitrate dehydrogenase 1 (IDH1) and IDH2 genes are mutated in acute myelogenous leukemia, low-grade glioma, intrahepatic cholangiocarcinoma, and chondrosarcomas. IDH1 and IDH2 normally function to convert isocitrate into alpha-ketoglutarate. Ho